Pressure Surface denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for pressure surface are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Pressure-Relieving Surfaces on Not-FDA-Approved Grounds

Support surfaces — specialty mattresses, overlays, and air-fluidized or low-air-loss beds — are regulated as medical devices by the FDA, not drugs. A "not-FDA-approved" denial in this context typically means the plan is asserting that the specific device has not received FDA clearance or approval, or that the requested use falls outside the device's cleared indications. This type of denial is relatively uncommon for mainstream support surfaces but may arise for newer or imported products.

## Why This Denial Is Appealable

Many support surfaces are marketed under FDA 510(k) clearance as Class II devices, meaning they have been found substantially equivalent to a legally marketed predicate device. FDA clearance is distinct from FDA "approval" (which applies to drugs and Class III devices), and plans sometimes conflate the two standards. If the requested surface holds valid FDA clearance, the denial premise is incorrect on its face and should be challenged with the device's regulatory documentation. Additionally, Medicare and Medicaid coverage of a surface category is strong supporting evidence of regulatory legitimacy.

## Federal Appeal Framework

• Internal appeal: ACA §2719 entitles you to at least one internal appeal. The denial must cite the specific regulatory basis; if it does not, request that in writing.
• External review: After exhausting internal review, request ACA §2719 external review. An independent reviewer can assess whether the plan's regulatory interpretation is correct.
• ERISA §503: For employer-sponsored plans, you are entitled under ERISA to receive the exact criteria and clinical reasoning used in the denial, including any regulatory basis cited.
• Timeline: External review requests are generally due within four months of the final internal denial. Expedited review is available when the standard timeline endangers health.

## Documents to Gather

• FDA clearance documentation: Obtain from the manufacturer the 510(k) clearance letter or other FDA authorization for the specific device, including its cleared indication for use.
• Prescriber letter: A letter confirming that the device is being used within its cleared indication and explaining why it is medically necessary for this patient.
• Wound and clinical documentation: Current wound assessment, diagnosis, and functional status supporting the clinical rationale.
• BCBS policy: Request the exact policy language on which the denial was based, including any device-approval standard the plan applies.

## Criteria-Mapping Structure

In your appeal letter, address the regulatory question directly: cite the FDA clearance number and cleared indication, then show that the prescribed use falls within that indication. Follow this with a criteria table mapping each policy requirement to supporting documentation. If the plan's policy does not actually require full FDA approval (as opposed to 510(k) clearance), state this explicitly and cite the policy language. Resolving the regulatory premise often resolves the denial.